Valencell, Inc. Joins Innovators’ Network at American Heart Association Center for Health Technology & Innovation Digital Science

OCTOBER 3, 2023

Valencell, Inc. Joins Innovators’ Network at American Heart Association Center for Health Technology & Innovation Digital Science

RALEIGH – Valencell, Inc. has joined the American Heart Association Center for Health Technology & Innovation’s (the Center) Innovators’ Network. The Center is focused on building and fostering health technology relationships to develop innovative and scalable solutions.

Hypertension is a leading cause of cardiovascular disease (CVD) and premature death in the United States and worldwide. It is estimated that 122.4 million US adults have hypertension according to the American Heart Association’s Heart Disease and Stroke Statistics 2023 Update .1 .3 

The American Heart Association has identified eight common risk factors, known as Life’s Essential 8™ that people can monitor to strive for ideal cardiovascular health: smoking status, physical activity, weight, diet, blood glucose, cholesterol, blood pressure (BP), and sleep. The Association’s CarePlans present actions people can take to work toward improving these factors and are designed so that any person can work toward improved health.

Much of Valencell’s innovative work in cuffless, calibration-free blood pressure monitoring is directed towards making cardiovascular health management easier for both patients and health care professionals. The key rationale is that improving the user experience in health care will result in greater adherence to evidence-based treatments and hence result in improved public health at reduced costs.  Valencell plans to incorporate the Association’s CarePlans which, in conjunction with regular BP measurements, help make it easier for patients to adopt cost-effective lifestyle changes for improved health and longevity.

“Valencell believes that by making blood pressure measurements much easier and more convenient, those managing hypertension will be more likely to adhere to evidence-based digital health solutions, such as the AHA’s CarePlans, for improving cardiovascular health at reduced cost to the health care system,” said Dr. Steven LeBoeuf, President and Co-Founder of Valencell. “Additionally, membership in the AHA’s Innovators’ Network provides opportunities to connect with others innovating in the health tech space as we pursue our mission to help patients and health care professionals improve BP adherence and health outcomes.”

###

About Valencell

Founded in 2006 and headquartered in Raleigh, NC, Valencell, Inc. is an acclaimed innovator of intuitive, accurate and easy to incorporate digital health solutions with a focus on addressing unmet needs in the prevention and management of chronic diseases such as hypertension, respiratory disease, and diabetes. Best known for their award-winning motion-tolerant heart rate monitoring inventions, their proprietary biometric sensor technology, algorithms, and machine learning analytics are protected by 150+ awarded patents, and power tens of millions of wearable and hearable devices on the market today.

Sources:

  1. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6324252/#hoi180022r1
  2. https://www.ahajournals.org/doi/10.1161/CIR.0000000000000558#R8-125 (unpublished AHA computation, based on methodology described by Heidenreich et al)
  3. https://www.ahajournals.org/doi/10.1161/CIR.0000000000000558#R8-83 (unpublished AHA computation, based on methodology described in Heidenreich et al).